Vietnam has the first factory producing cancer treatment drugs.

Binh Dinh Cancer Drug Factory will supply 70 million pills per year, selling at 40% cheaper than Europe, inaugurated on December 2.

The factory belongs to Binh Dinh Pharmaceutical and Medical Equipment Company (Bidiphar) with a capital of 500 billion VND, in addition to tablets, it will supply 3 million injectable products each year.

With an area of 15,350 m2, the factory located in Nhon Hoi economic zone started construction in August 2018, was granted a GMP-WHO certificate by the Ministry of Health and is on the way to upgrading to GMP-EU standards.

To meet this standard, the factory is invested in a fully automatic, closed equipment line, applying modern pharmaceutical production technologies such as: sterile drug production technology, isolation technology, freeze-drying, automatic packaging - traceability control, control, automatic data collection...

The factory was put into operation to serve the production of Bidiphar's main pharmaceutical products developed from the state-level science and technology project with the largest scale and budget in the country in the medical field at the time of implementation from 2014-2019.

Ribbon cutting ceremony to inaugurate the factory. Photo: Bidiphar — Ribbon cutting ceremony to inaugurate the factory. Photo: *Bidiphar*

Ms. Pham Thi Thanh Huong - General Director of Bidiphar said that the inauguration of the new cancer treatment drug factory with two injection and pill lines will improve production capacity, ensure drug quality as well as contribute to proactively producing cancer drugs domestically at reasonable costs. The factory will also contribute to improving industrial production capacity, contributing to job creation and socio-economic development of Binh Dinh province.

Bidiphar has been developing cancer treatment products for more than 10 years. This enterprise has supplied more than 5 million units of products to the market. Bidiphar's cancer treatment product line is used in central hospitals such as K Hospital, Ho Chi Minh City Oncology Hospital, Cho Ray Hospital, Bach Mai Hospital and medical facilities with oncology departments nationwide. The price of the products is on average 40% lower than European drugs and 20% lower than Asian drugs.

Guests visit the factory on December 2. Photo: Bidiphar — Guests visit the factory on December 2. Photo: *Bidiphar*

On the same day, Bidiphar held a groundbreaking ceremony for a small-volume sterile drug factory according to GMP-EU standards. The factory covers an area of 25,000 m2 and is located in the unit's high-tech pharmaceutical factory cluster, with a total investment of VND840 billion. It is expected that by 2027, the factory will be put into operation to produce injectable drugs, eye drops and other sterile drugs. The capacity is 120 million products per year.

According to Bidiphar representative, this is one of the major investment projects in the sustainable development strategy, contributing to the development of the pharmaceutical industry. The unit expects that when the large-capacity factory comes into operation, it will help proactively stabilize drug prices, meeting the Government's strategic goal of "domestic drugs meeting 80% of treatment needs by 2030".

Attending the inauguration ceremony, Vice Chairman of the Provincial People's Committee Lam Hai Giang affirmed that the project of the cancer treatment drug factory and the groundbreaking ceremony of the small-volume sterile drug factory of Bidiphar are proof that Binh Dinh has many advantages and potentials to attract domestic and foreign investors. According to the provincial leaders, this event is a new driving force in the province's journey of developing high-tech industry in the coming years.

Hoai Phuong

Source link